Glycemic and Non-Glycemic Effects of Teneligliptin
Journal of Pharmaceutical Research International,
The gut enzymes are released in response to intake of meal, those are GLP-I (glucagon link peptide-I) & GIP (glucose-dependent insulin tropic polypeptide) along with DPP-4(Dipeptidyl peptidase-4). GLP-I has vital role in control of glucose levels and it may also has capacity reduce body weight and it can manage some micro & macro-vascular complications. Unfortunately it has very shorter half-life 1-2 min, and eventually it was degraded by DPP-4 enzyme. Therefore GLP-I has ineffective to perform its tasks. To overcome this incidence essential to inhibit DPP-4 enzyme is benefited in diabetics and in non diabetics suffering with micro, macro vascular complications. Ubiquitous Dipeptidyl peptidase (DPP) - 4 has pleiotropic effects because it is widely distributed other than intestine. DPP-4 enzyme inhibition has a promising effect on glycemic control. DPP-4 inhibition is also involved in the improvement of non-glycemic effects as directly or indirectly the DPP-4 enzyme is linked with some pathological conditions of particular organs, such as DPP-4 is linked with the intestinal secretion of triglycerides, and DPP-4 is expressed in the glomerulus in uncontrolled diabetics which in turn leads to nephritis. DPP-4 release strongly correlates with adipocyte size, potentially representing an important source of DPP-4 in obesity. DPP-4 inhibition produces an anti-inflammatory activity because the activity of DPP-4 results in reduced production of cytokines including interleukins and interferon-G. All these anti-inflammatory agents are inhibited by the DPP-4 enzyme which can lead to pathogenesis of cardiovascular diseases and provokes atherosclerosis & psoriasis. Serum sodium and brain natriuretic peptide (BNP) levels are also regulated by inhibition of the DPP-4 enzyme and which can produce vascular protection & regulates blood pressure. Teneligliptin is a recently developed oral DPP-4 inhibitor indicated for the management of T2DM in adults along with diet and exercise. Teneligliptin is recently available in India and is also available in combination with other oral hypoglycemic agents at affordable prices. This review is aimed at exploring the status of teneligliptin with emphasis on its glycemic effects and non-glycemic clinical benefits associated with increasing GLP-1 & GIP.
- dipeptidyl peptidase-4
- pleiotropic effects.
How to Cite
Nabeno M, Akahoshi F, Kishida H, Miyaguchi I, Tanaka Y, Ishii S, Kadowaki T. A comparative study of the binding modes of recently launched dipeptidyl peptidase IV inhibitors in the active site. Biochem Biophys Res Commun. 2013; 434(2):191-6.
Xiao-Wu Chen, Zhi-Xu He, Zhi-Wei Zhou, Tianxin Yang, Xueji Zhang, Yin-Xue Yang, Wei Duan and Shu-Feng Zhou. Clinical pharmacology of dipeptidyl peptidase 4 inhibitors indicated for the treatment of type 2 diabetes mellitus. Clinical and Experimental Pharmacology and Physiology. 2015;42:999-1024.
Maladkar M, Sankar S, Kamat K. Teneligliptin: Heralding change in type 2 diabetes. Journal of Diabetes Mellitus. 2016;6:113-31.
Röhrborn D, Wronkowitz N, Eckel J. DPP4 in Diabetes. Frontiers in Immunology. 2015;6:1-20.
Yoshinobu Nakamarua B, Chie Emotoa, Makiko Shimizua, Hiroshi Yamazakia. Human pharmacokinetic profiling of the dipeptidyl peptidase-IV inhibitor teneligliptin using physiologically based pharmacokinetic modeling. Biopharm. Drug Dispos. 2015;36:148– 162.
Eto T, Inoue S, Kadowaki T. Effects of once daily teneligliptin on 24h blood glucose control & safety in Japanese patients with Type-2 diabetes mellitus - a 4-week randomised double blind placebo controlled trial. J Diabetes Obes Metab. 2012;29:999.
Gary A. Herman, Arthur Bergman, Fang Liu, et al. Pharmacokinetics and pharmacodynamic effects of the oral DPP-4 inhibitor sitagliptin in middle-aged obese subjects. J Clin Pharmacol. 2006;46:876-86.
Xiaoxuan Li, Xuefei Huang, Chongfei Bai, Dalian Qin, Shousong Cao, Qibing Mei, Yun Ye, Jianming Wu. Efficacy and safety of teneligliptin in patients with type 2 diabetes mellitus: A systematic review and meta-analysis of randomized controlled trials. Front. Pharmacol. 2018;9:449.
Annayya R. Aroor, James R. Sowers, Guanghong Jia, Vincent G. DeMarco. Pleiotropic effects of the dipeptidylpe-ptidase-4 inhibitors on the cardiovascular system. Am J Physiol Heart Circ Physiol. 2014;307:H477–H492.
Hsieh J, Longuet C, Baker CL, Qin B, Federico LM, Drucker DJ, Adeli K. The glucagon- like peptide 1 receptor is essential for postprandial lipoprotein synthesis and secretion in hamsters and mice. Diabetologia. 2010;53:552–561.
Masuda D, Koybayashi T, Okada T, Nakaoka H, Kawase R, Nakatani K, Ohama T, Nishida M, Matsuyama A, Komuro I, Yamashita S. Treatment with linagliptin can attenuate postprandial hyperlipidemia (abstract). In: Proceedings of the 73rd Annual Scientific Sessions of the American Diabetes Association. Chicago, IL. 2013;A77.
Noda Y, Miyoshi T, Oe H, Ohno Y, Nakamura K, Toh N, Kohno K, Morita H, Kusano K, Ito H. Alogliptin ameliorates postprandial lipemia and postprandial endothelial dysfunction in non-diabetic subjects: A preliminary report. Cardiovasc Diabetol. 2013;12:8.
Matikainen N, Manttari S, Schweizer A, Ulvestad A, Mills D, Dunning BE, Foley JE, Taskinen MR. Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes. Diabetologia. 2006;49:2049–57.
Tremblay AJ, Lamarche B, Deacon CF, Weisnagel SJ, Couture P. Effect of sitagliptin therapy on postprandial lipoprotein levels in patients with type 2 diabetes. Diabetes Obes Metab. 2011; 13:366–73.
Kusunoki, M, Sato D, Nakamura T, Oshida Y, Tsutsui H, Natsume Y, Miyata T. DPP-4 inhibitor teneligliptin improves insulin resistance and serum lipid profile in japanese patients with type 2 diabetes. Drug Research. 2014;65(10):532–34.
Vyshnavi V. Supriya, Bandaru Siva Subrahmanyam T, Eggadi Venkateshwarlu, Bandaru Sheshagiri Sharvana Bhava. Comparison of teneligliptin and atorvastatin on lipid profile in patients with type 2 daiabetes mellitus. Curr Res Diabetes Obes J. 2018:8(1).
Elleder M, Stejskal J. Induction of dipeptidyl peptidase IV activity in human renal glomeruli–A histochemical study. Acta Histochem. 1985;77:75– 78.
Stefanovic V, Ardaillou N, Vlahovic P, Placier S, Ronco P, Ardaillou R. Interferon- gamma induces dipeptidylpeptidase IV expression in human glomerular epithelial cells. Immunology. 1993;80(3):465–470.
Per-Henric. Groop ME, Cooper V. Perkovic et al. Dipeptidyl peptidase-4 inhibition with linagliptin and effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: Rationale and design of the MARLINAT2D trial. Diabetes and Vascular Disease Research. 2015;12(6):455–462.
Per-Henrik Groop, Mark E. Cooper, Vlado Perkovic, Angela Emser, Hans- Juergen Woerle, Maximilian von Eynatten, Linagliptin lowers albuminuria on top of recommended standard treatment in patients with type 2 diabetes and renal dysfunction. Diabetes Care. 2013;36(11): 3460-8.
Hashikata T, Yamaoka-Tojo M, Kakizaki R, Nemoto T, Fujiyoshi K, Namba S, Kitasato L, Hashimoto T, Kameda R, Maekawa E, Shimohama T, Tojo T, Ako J. Teneligliptin improves left ventricular diastolic function and endothelial function in patients with diabetes. Heart Vessels; 2015.
Dicker D. DPP-4 inhibitors. Impact on glycemic control and cardiovascular risk factors. Diabetes Care. 2011;34(Suppl 2): S276–S278.
Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: Systematic review and meta-analysis. JAMA. 2007;298:194–206.
Scheen AJ. A review of gliptins in 2011. Expert Opin Pharmacother. 2012;13:81–99.
Daniela Lamers, Susanne Famulla, Nina Wronkowitz, Sonja Hartwig, et al. Dipeptidyl peptidase 4 is a novel adipokine potentially linking obesity to the metabolic syndrome. Diabetes. 2011;60(7):1917- 25.
Zhong J, Rao X, Rajagopalan S. An emerging role of dipeptidyl peptidase 4 (DPP4) beyond glucose control: Potential implications in cardiovascular disease. Atherosclerosis. 2013;226(2):305–314.
Feuerer M, Herrero L, Cipolletta D, Naaz A, Wong J, Nayer A, Lee J, Goldfine AB, Benoist C, Shoelson S, Mathis D. Lean, but not obese, fat is enriched for a unique population of regulatory T cells that affect metabolic parameters. Nat Med. 2009;15: 930–39.
Flegal KM, Carroll MD, Kit BK, Ogden CL. Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999–2010. JAMA. 2012;307:491–7.
Freemantle N. Commentary: What can we learn from the continuing regulatory focus on the thiazolidinediones? BMJ. 2010; 341:c4812.
Friedrich C, Emser A, Woerle HJ, Graefe-Mody U. Renal impairment has no clinically relevant effect on the long-term exposure of linagliptin in patients with type 2 diabetes. Am J Ther. 2013;20:618–21.
Fujisaka S, Usui I, Kanatani Y, Ikutani M, Takasaki I, Tsuneyama K, Tabuchi Y, Bukhari A, Yamazaki Y, Suzuki H, Senda S, Aminuddin A, Nagai Y, Takatsu K, Kobayashi M, Tobe K. Telmisartan improves insulin resistance and modulates adipose tissue macrophage polarization in high-fat-fed mice. Endocrinology. 2011; 152:1789–99.
Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008;358:580–51.
Gallwitz B, Rosenstock J, Rauch T, Bhattacharya S, Patel S, von Eynatten M, Dugi KA, Woerle HJ. 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: A randomised, double-blind, non- inferiority trial. Lancet. 2012;380:475–83.
Giorda CB, Nada E, Tartaglino B, Marafetti L, Gnavi R. A systematic review of acute pancreatitis as an adverse event of type 2 diabetes drugs: From hard facts to a balanced position. Diabetes Obes Metab. 2014;16(11):1041-7.
Graefe-Mody U, Friedrich C, Port A, Ring A, Retlich S, Heise T, Halabi A, Woerle HJ. Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin. Diabetes Obes Metab. 2011;13:939–946.
Lago RM, Singh PP, Nesto RW. Diabetes and hypertension. Nat Clin Pract Endocrinol Metab. 2007;3:667.
Von Eynatten M, Gong Y, Emser A, Woerle HJ. Efficacy and safety of linagliptin in type 2 diabetes subjects at high risk for renal and cardiovascular disease: a pooled analysis of six phase III clinical trials. Cardiovasc Diabetol. 2013; 12:60.
Mistry GC, Maes AL, Lasseter KC, Davies MJ, Gottesdiener KM, Wagner JA, Herman GA. Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on blood pressure in nondiabetic patients with mild to moderate hypertension. J Clin Pharmacol. 2008;48: 592–8.
Monami M, Ahren B, Dicembrini I, Mannucci E. Dipeptidyl peptidase-4 inhibitors and cardiovascular risk: A meta-analysis of randomized clinical trials. Diabetes Obes Metab. 2013;15:112–20.
Ogawa S, Ishiki M, Nako K, Okamura M, Senda M, Mori T, Ito S. Sitagliptin, a dipeptidyl peptidase-4 inhibitor, decreases systolic blood pressure in Japanese hypertensive patients with type 2 diabetes. Tohoku J Exp Med. 2011;223:133–5.
Von Websky K, Reichetzeder C, Hocher B. Physiology and pathophysiology of incretins in the kidney. Current Opinion in Nephrology and Hypertension. 2014;23: 54-60.
Girardi AC, Degray BC, Nagy T, Biemesderfer, Aronson P. Association of Na+-H+ exchanger isoform NHE3 and dipeptidyl peptidase IV in the renal proximal tubule. The Journal of Biological Chemistry. 2001;276:46671-7.
Girardi AC, Knauf F, Demuth HU, Aronson PS. Role of dipeptidyl peptidase IV in regulating activity of Na+/H+ exchanger isoform NHE3 in proximal tubule cells. The American Journal of Physiology—Cell Physiology. 2004;287:C1238-C1245.
Mason RP, Jacob RF, Kubant R, Walter MF, Bellamine A, Jacoby A, Mizuno Y, Malinski T. Effect of enhanced glycemic control with saxagliptin on endothelial nitric oxide release and CD40 levels in obese rats. Journal of Atherosclerosis and Thrombosis. 2011;18:774-83.
Ishii M, Shibata R, Kondo K, Kambara T, Shimizu Y, Tanigawa T, Bando YK, Nishimura M, Ouchi N, Murohara T. Vildagliptin stimulates endothelial cell network formation and ischemia-induced revascularization via an endothelial nitric oxide synthase-dependent mechanism. The Journal of Biological Chemistry. 2014; 289:27235-45.
Shih CM, Chen YH, Lin YW, Tsao NW, Wu SC, Kao YT, Chiang KH, Li CY, Chang NC, Lin CY, Huang CY, Lin FY. MK-0626, a dipeptidyl peptidase-4 inhibitor, improves neovascularization by increasing both the number of circulating endothelial progenitor cells and endothelial nitric oxide synthetase expression. Current Medicinal Chemistry. 2014;21:2012-22.
Brandt I, Lambeir AM, Ketelslegers JM, Vanderheyden M, Scharpé S, De Meester I. Dipeptidyl- peptidase IV converts intact B-type natriuretic peptide into its des-serpro form. Clinical Chemistry. 2006;52: 82-87.
Mentlein R, Gallwitz B, Schmidt WE. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7–36) amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem. 1993;214:829–35.
Ussher JR, Drucker DJ. Cardiovascular biology of the incretin system. Endocr Rev. 2012;33:187–215.
Chihiro Moriya, Hiroaki Satoh. Teneligliptin decreases uric acid levels by reducing xanthine dehydrogenase expression in white adipose tissue of male wistar rats. J Diabetes Res; 2016.
Nishioka T, Shinohara M, Tanimoto N, Kumagai C, Hashimoto K. Sitagliptin, a dipeptidyl peptidase-IV inhibitor, improves psoriasis. Dermatology. 2012;224:20–21.
Lynch M, Tobin AM, Ahern T, O’Shea D, Kirby B. Sitagliptin for severe psoriasis. Clin Exp Dermatol. 2014;39:841–842.
Nagai H, Fujiwara S, Takahashi Y, Nishigori C. Ameliorating effect of the novel dipeptidyl peptidase-4 inhibitor teneligliptin on psoriasis: a report of two cases. J Dermatol. 2015;42:1094–97.
Kim SC, Schneeweiss S, Glynn RJ, Doherty M, Goldfine AB, Solomon DH. Dipeptidyl peptidase-4 inhibitors in type 2 diabetes may reduce the risk of autoimmune diseases: A population-based cohort study. Ann Rheum Dis. 2015;74: 1968–1975.
Novelli M, Savoia P, Fierro MT, Verrone A, Quaglino P, Bernengo MG. Keratinocytes express dipeptidyl-peptidase IV (CD26) in benign and malignant skin diseases. Br J Dermatol. 1996;134:1052–56.
Van Lingen RG, van de Kerkhof PC, Seyger MM, de Jong EM, van Rens DW, Poll MK, et al. CD26/dipeptidyl-peptidase IV in psoriatic skin: Upregulation and topographical changes. Br J Dermatol. 2008;158:1264–72.
Van Lingen RG, Poll MK, Seyger MM, de Jong EM, van de Kerkhof PC, van Erp PE. Distribution of dipeptidyl-peptidase IV on keratinocytes in the margin zone of a psoriatic lesion: A comparison with hyper-proliferation and aberrant differentiation markers. Arch Dermatol Res. 2008;300: 561–67.
Thielitz A, Reinhold D, Vetter R, Ute Bank, Martin Helmuth, Roland Hartig, et al. Inhibitors of dipeptidyl peptidase IV and aminopeptidase N target major pathogenetic steps in acne initiation. J Invest Dermatol. 2007;127:1042–51.
Kadowaki T, Kondo K. Efficacy, safety and dose response relationship of teneligliptin, a dipeptidyl peptidase 4 inhibitor, in Japanese patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2013;15: 810 8.
Kadowaki T, Kondo K. Efficacy and safety of teneligliptin added to glimepiride in Japanese patients with type 2 diabetes mellitus: A randomized, double blind, placebo controlled study with an open label, long term extension. Diabetes Obes Metab. 2014;16:418 25.
Kadowaki T, Kondo K. Efficacy and safety of teneligliptin in combination with pioglitazone in Japanese patients with type 2 diabetes mellitus. J Diabetes Investig. 2013;4:576 84.
Kadowaki T, Marubayashi F, Yokota S, Katoh M, Iijima H. Safety and efficacy of teneligliptin in Japanese patients with type 2 diabetes mellitus: A pooled analysis of two phase III clinical studies. Expert Opin Pharmacother. 2015;16:971 81.
Singh AK. Efficacy and safety of teneligliptin, Indian. J Endocr Metab. 2017;21:11-7
Stonehouse AH, Darsow T, Maggs DG. Incretin-based therapies. J Diabetes. 2012;4:55–67.
Dailey MJ, Moran TH. Glucagon-like peptide 1 and appetite. Trends Endocrinol. Metab. 2013;24:85–91.
Abstract View: 960 times
PDF Download: 652 times